U.S. Patent & Trademark Office (USPTO) Archives

ElectroCore expands nerve stimulation IP portfolio

ElectroCore (Nasdaq:ECOR) announced today that the U.S. Patent and Trademark office (USPTO) issued it a new nerve stimulation patent.

The new patent (No. 11,839,764 ) relates to a system for stimulating a nerve target in the head or neck of a patient. It covers the treatment of various disorders, such as primary headache. It’s titled “Systems and Methods for Treating a Medical Condition with an Electrical Stimulation Treatment Regimen.”

Issued today, Dec. 12, the patent relates to a system that includes downloadable software on, for example a mobile device. Its configuration allows it to control a parameter of the electrical impulses delivered by a stimulator for targeting nerves.

“We continue to grow our intellectual property portfolio,” said Joshua Lev, chief strategy officer of electroCore. “This new patent strengthens our position around systems that utilize mobile applications to control stimulators that treat various disorders such as primary…

NeuroOne is pursuing drug delivery with neural probes

NeuroOne Medical Technologies (Nasdaq:NMTC) announced today that it received a patent for drug delivery with neural probe devices.

The United States Patent and Trademark Office (USPTO) issued the patent titled “Agent-Delivering Neural Probe Devices and Related Systems and Methods.” It covers novel electrodes that can operate as a standard neural electrode that delivers a treatment agent to a target area of the brain.

A step into the drug delivery space would mark further progress for NeuroOne, which develops thin-film electrode technologies.

The company already has a patent portfolio that includes both neural and spinal cord electrodes. Their unique structures optimize the functionality and minimized profile of those electrodes.

Get the full story at our sister site, Drug Delivery Business News.

HeartBeam wins AI-related patent for handheld vector ECG

[Image courtesy of HeartBeam]HeartBeam (Nasaq:BEAT) announced today that it received a key patent relating to AI capabilities for its AIMIGo system.

The U.S. Patent and Trademark Office (USPTO) issued the allowance for a patent titled “Hand Held Device for Automatic Cardiac Risk and Diagnostic Assessment.” The patent describes a system that combines recorded cardiac signals from AIMIGo with the patient’s symptoms and cardiac risk factors. Together, this calculates a cardiac risk score to provide simplified diagnostic information and actionable instructions.

Santa Clara, California-based HeartBeam said this aims to replicate the decision-making process of a physician assessing cardiac symptoms. However, with AIMIGo, it occurs remotely and in an automated manner.

HeartBeam developed AIMIGo as a personal, portable vector electrocardiogram (VECG) system. It assists patients and clinicians in assessing cardiac symptoms. It utilizes a reusable, credit card-…

HeartBeam picks up patent for 12-lead ECG patch

HeartBeam (Nasdaq:BEAT) announced today that the U.S. Patent and Trademark Office issued a patent for its 12-lead electrocardiogram (ECG) patch.

Santa Clara, California-based HeartBeam designed its ECG patch monitor for detecting acute coronary syndrome (ACS) and cardiac arrhythmia.

The company said in a news release that the granted patent builds on its portfolio enabling 12-lead ECG diagnostics outside the medical setting. HeartBeam’s ECG can aid physicians in arrhythmia detection and ACS diagnosis that includes heart attack and angina.

“This patent provides additional intellectual property protection for our breakthrough ECG patch technology, offering 12-lead ECG capability in the form of a simple patch that is similar in size and shape to existing single-lead ECG patch monitors in the market today,” said HeartBeam CEO and founder Branislav Vajdic. “Our 12-lead ECG patch technology offers the potential to bring a level of diagnostic accuracy con…